Gilead Sciences (GILD) Inventory (2009 - 2026)

Gilead Sciences (GILD) has reported Inventory for 18 consecutive years, with $2.0 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Inventory rose 7.01% year-over-year to $2.0 billion; the trailing twelve-month figure through Jun 2026 stood at $2.0 billion (up 7.01% YoY), and the FY2025 full-year result was $1.8 billion, up 3.74% from the prior year.
• Inventory improved to $2.0 billion in Q2 2026 per GILD's latest filing, from $1.9 billion in the prior quarter.
• Across five years, Inventory topped out at $2.0 billion in Q2 2024 and bottomed at $1.5 billion in Q3 2022.
• Historically, Inventory has averaged $1.7 billion across 5 years, with a median of $1.8 billion in 2025.
• The sharpest annual moves came in 2022 and 2024: Inventory decreased 16.69% in 2022, then grew 24.07% in 2024.
• Over 5 years, Inventory stood at $1.5 billion in 2022, then advanced by 18.58% to $1.8 billion in 2023, then slipped by 4.31% to $1.7 billion in 2024, then advanced by 3.74% to $1.8 billion in 2025, then rose by 10.09% to $2.0 billion in 2026.
• According to Business Quant data, Inventory over the past three periods registered $2.0 billion, $1.9 billion, and $1.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.